1
|
Houpert R, Almont T, Belahreche R, Faro M, Okouango J, Vestris M, Macni J, Pierre-Louis O, Montabord C, Beaubrun-Renard M, Soumah N, Boisseau M, Véronique-Baudin J, Joachim C. A population-based analysis of hematological malignancies from a French-West-Indies cancer registry's data (2009-2018). BMC Cancer 2023; 23:1197. [PMID: 38057723 DOI: 10.1186/s12885-023-11666-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 11/22/2023] [Indexed: 12/08/2023] Open
Abstract
BACKGROUND A worldwide increased incidence of HM has been marked in recent decades. Therefore, to update epidemiological characteristics of HM in a French West Indies territory, we have performed analysis through Martinique's population-based cancer registry database. METHODS We included cancer case data, from 2009-2018, coded in strict compliance with international standards set by International Agency for Research on Cancer. We calculated standardized incidence rates, cumulative rate (ages 0-74), and temporal trends for cases and deaths using the global population standard, by sex and five age group. Mortality rates were obtained from the French Epidemiology Center on Medical Causes of Death (CépiDc). RESULTS One thousand forty seven new cases and 674 deaths from HM were recorded, of which 501 MM (47.8%), 377 LMNH (36%), 123 LAM (11.8%), and 46 LH (4.4%) were reported in both sexes. MM is one of the hematological malignancies with the highest incidence in Martinique among men. Temporal trends of incidence rates for all HM decreased overall in both sexes, except for MM in men. There is significant variability in mortality rates for both sexes. In addition, over the period, the temporal trends of mortality rates for all HMs has decreased overall. Gender-specific rates, between 2009 and 2018, showed that all lymphoid HM have a multimodal distribution curve that increased with age. CONCLUSIONS Characteristics of HM in Martinique over the reporting periods differ from mainland France. Higher incidences have been observed, particularly for MM, and non-significant sub-mortality is observed compared to mainland France. Moreover, temporal distribution of mortality and incidence trends had decreased over the reporting periods except for MM. Our results showed similarities with African-Americans groups in United States and in particular an equivalence in the frequency distribution of diagnosed HM. However, SMR remains lower compared to US black ethnic groups. Our results contributed to expanding knowledge on the epidemiology of HM with Caribbean data.
Collapse
Affiliation(s)
- Rémi Houpert
- Oncology Hematology Urology Department, Oncology Research & Development Unit (UF3596), University Hospital of Martinique, Fort-de-France, Martinique.
| | - Thierry Almont
- Oncology Hematology Urology Department, Oncology Research & Development Unit (UF3596), University Hospital of Martinique, Fort-de-France, Martinique
| | - Rostom Belahreche
- Hematology Unit, Oncology Hematology Urology Department, University Hospital of Martinique, Fort-de-France, Martinique
| | - Mamadi Faro
- Hematology Unit, Oncology Hematology Urology Department, University Hospital of Martinique, Fort-de-France, Martinique
| | - Jennie Okouango
- Hematology Unit, Oncology Hematology Urology Department, University Hospital of Martinique, Fort-de-France, Martinique
| | - Mylène Vestris
- Oncology Hematology Urology Department, General Cancer Registry of Martinique (UF1441), University Hospital of Martinique, Fort-de-France, Martinique
| | - Jonathan Macni
- Oncology Hematology Urology Department, General Cancer Registry of Martinique (UF1441), University Hospital of Martinique, Fort-de-France, Martinique
| | - Olivier Pierre-Louis
- Sciences Technologies Environment Department, Cellular Biology Physiology and Pathology, West Indies University, Pole of Martinique, Martinique
| | - Christelle Montabord
- Oncology Hematology Urology Department, Oncology Research & Development Unit (UF3596), University Hospital of Martinique, Fort-de-France, Martinique
| | - Murielle Beaubrun-Renard
- Oncology Hematology Urology Department, General Cancer Registry of Martinique (UF1441), University Hospital of Martinique, Fort-de-France, Martinique
| | - Naby Soumah
- Hematology Unit, Oncology Hematology Urology Department, University Hospital of Martinique, Fort-de-France, Martinique
| | - Martial Boisseau
- Hematology Unit, Oncology Hematology Urology Department, University Hospital of Martinique, Fort-de-France, Martinique
| | - Jacqueline Véronique-Baudin
- Oncology Hematology Urology Department, Oncology Research & Development Unit (UF3596), University Hospital of Martinique, Fort-de-France, Martinique
| | - Clarisse Joachim
- Oncology Department, University Hospital of Martinique, Fort-de-France, Martinique
| |
Collapse
|
2
|
Beaubrun-Renard M, Ulric-Gervaise S, Veronique-Baudin J, Macni J, Almont T, Aline-Fardin A, Furtos C, Jean-Laurent M, Escarmant P, Bougas S, Cabie A, Joachim C. Breast cancer time to treatment in Martinique: predictive factors and effect on survival. Public Health 2023; 225:147-150. [PMID: 37925839 DOI: 10.1016/j.puhe.2023.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 08/10/2023] [Accepted: 09/13/2023] [Indexed: 11/07/2023]
Abstract
BACKGROUND Martinique is the second French Region with the lowest physician-to-population ratio, which may affect waiting times for access to care. OBJECTIVES To assess (i) factors influencing waiting times from diagnosis to cancer-related treatments in breast cancer women in Martinique, and (ii) the impact of waiting times on patients' survival. STUDY DESIGN Retrospective observational study. METHODS Data on women diagnosed with invasive breast cancer between 1st January 2013 and 31st December 2017 and initially treated by surgery were extracted from the Martinique population-based registry. A cox model was performed to find predictive factors for waiting times. A log-rank test was used to compare time-to-treatment between groups. RESULTS In total, 713 patients were included (mean age: 58 ± 13). Median time from diagnosis to surgery was 40 [25-60] days. Age at diagnosis was found to predict variations in waiting times. Patients > 75 had longer waiting time to surgery than those < 40 or [40-50] (P = 0.016 and P < 0.001, respectively). Women with a time-to-treatment ≥ 4 months had a significant lower survival (P < 0.01). CONCLUSIONS Specific interventions are needed to improve waiting time from diagnosis to initial treatment, as they are longer than recommended and affect survival time.
Collapse
Affiliation(s)
- M Beaubrun-Renard
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France; PCCEI, Université de Montpellier, INSERM, EFS, Université Antilles, Montpellier, France.
| | - S Ulric-Gervaise
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - J Veronique-Baudin
- UF 3596 Recherche en cancérologie hématologie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - J Macni
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - T Almont
- UF 3596 Recherche en cancérologie hématologie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - A Aline-Fardin
- Laboratoire d'anatomopathologie, Pôle de Biologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - C Furtos
- UF 1450 - Oncologie Médicale Hospitalisation de Semaine, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - M Jean-Laurent
- Unité de chirurgie gynécologique et mammaire, Maison de la Femme de la Mère et de l'Enfant, CHU de Martinique, Fort-de-France, Martinique, France
| | - P Escarmant
- Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - S Bougas
- UF 1401 Radiothérapie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - A Cabie
- PCCEI, Université de Montpellier, INSERM, EFS, Université Antilles, Montpellier, France; Service des maladies infectieuses et tropicales, Martinique, CHU de Martinique, Fort-de-France, Martinique, France; CIC-1424, INSERM, CHU de Martinique, Fort-de-France, Martinique, France
| | - C Joachim
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| |
Collapse
|
3
|
Medina HN, Penedo FJ, Joachim C, Deloumeaux J, Koru-Sengul T, Macni J, Bhakkan B, Peruvien J, Schlumbrecht MP, Pinheiro PS. Endometrial cancer risk and trends among distinct African descent populations. Cancer 2023; 129:2717-2726. [PMID: 37357566 DOI: 10.1002/cncr.34789] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 02/23/2023] [Accepted: 03/08/2023] [Indexed: 06/27/2023]
Abstract
BACKGROUND Endometrial cancer (EC) is the fourth most common cancer among Black women in the United States, a population disproportionately affected by aggressive nonendometrioid subtypes (e.g., serous, carcinosarcoma). To examine EC vulnerability among a wider spectrum of African descent populations, a comparison between Black women residing in different countries, rather than in the United States alone, is needed. METHODS The authors analyzed 34,789 EC cases from Florida (FL) (2005-2018), Martinique (2005-2018), and Guadeloupe (2008-2018) based on cancer registry data. Age-adjusted incidence rates, incidence rate ratios (IRRs), and annual percent changes (APC) in trends were estimated for Black populations residing in the United States (non-Hispanic Blacks [NHB]) and Caribbean. The US non-Hispanic White (NHW) population was used as a reference. RESULTS Caribbean Black women had the lowest rates for endometrioid and nonendometrioid subtypes. Nonendometrioid types were most common among US (FL) NHBs (9.2 per 100,000), 2.6 times greater than NHWs (IRR, 2.60; 95% confidence interval [CI], 2.44-2.76). For endometrioid EC, rates increased 1.8% (95% CI, 0.1-3.5) yearly from 2005 to 2018 for US (FL) NHBs and 1.2% (95% CI, 0.9-1.6) for US (FL) NHWs whereas no change was observed for Caribbean Blacks. For nonendometroid carcinomas, rates increased 5.6% (95% CI, 4.0-7.2) among US (FL) NHB, 4.4% (95% CI, 0.3-8.6) for Caribbean Black, and 3.9% for US (FL) NHW women (95% CI, 2.4-5.5). CONCLUSIONS Lower rates of nonendometrioid EC among Caribbean Black women suggest that vulnerability for these aggressive tumor subtypes may not currently be an overarching African ancestry disparity. Most importantly, there is an alarmingly increasing trend in nonendometrioid across all populations studied, which warrants further surveillance and etiological research for this particular subtype. PLAIN LANGUAGE SUMMARY We analyze population-based incidence rates and trends of endometrial cancer (EC) for African descent populations residing in different countries (i.e., United States, Martinique, Guadeloupe) to examine whether EC vulnerability among Black women is socio-environmental or more ancestry-specific in nature. The increased EC risk was not uniform across all Black women since the Caribbean had the lowest rates (for endometrioid and nonendometrioid histology subtypes). Regardless, from 2005 to 2018, there was an increasing trajectory of nonendometrioid EC for all groups, regardless of race.
Collapse
Affiliation(s)
- Heidy N Medina
- Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida, USA
| | - Frank J Penedo
- Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
- Department of Psychology, University of Miami, Miami, Florida, USA
| | - Clarisse Joachim
- Martinique Cancer Registry, University Hospital of Martinique, Martinique, France
| | | | - Tulay Koru-Sengul
- Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida, USA
- Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
| | - Jonathan Macni
- Martinique Cancer Registry, University Hospital of Martinique, Martinique, France
| | - Bernard Bhakkan
- Guadeloupe Cancer Registry, University Hospital of Guadeloupe, Guadeloupe, France
| | - Jessica Peruvien
- Guadeloupe Cancer Registry, University Hospital of Guadeloupe, Guadeloupe, France
| | - Matthew P Schlumbrecht
- Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
- Department of Obstetrics & Gynecology, University of Miami School of Medicine, Miami, Florida, USA
| | - Paulo S Pinheiro
- Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida, USA
- Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
| |
Collapse
|
4
|
Lin L, Almont T, Beaubrun M, Macni J, Pierre-Louis A, Zabulon A, Draganescu C, Lin L, Sabbah N, Drame M, Veronique-Baudin J, Joachim C. Overall survival of patients with thyroid cancer in Martinique (2008-2018). BMC Cancer 2023; 23:739. [PMID: 37563603 PMCID: PMC10413767 DOI: 10.1186/s12885-023-11072-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 06/14/2023] [Indexed: 08/12/2023] Open
Abstract
BACKGROUND Thyroid cancer (TC) overall survival at 5 years was estimated at 97% in mainland France over 2010-2015. Its prognosis is known to be affected by patient age, tumor histology, size, and extension. This study aims to describe overall survival of thyroid cancer patients diagnosed between 2008 and 2018 in Martinique. METHODS We included in this retrospective analytical study all patients who were diagnosed with thyroid cancer. An overall survival analysis at 1, 3 and 5 years of thyroid cancer patients diagnosed in Martinique from 2008 to 2018 was conducted. Prognostic factors associated with survival have been identified. Stage at diagnosis and patterns of care among thyroid cancer patients were analyzed. RESULTS A total of 323 thyroid cancer patients were registered between 2008 and 2018. Papillary carcinomas represented 83% of diagnoses. Local stage or locally advanced invasion was found in 264 (88%) patients. 221 Multidisciplinary Teams reports files were reviewed. The overall survival observed in this population is 97% [93-99] at 1 year, 93% [88-97] at 3 years and 91% [85-95] at 5 years. Anaplastic, poorly differentiated and medullar tumors had lower survival rates at 5 years (39% [13-65]) compared to papillary tumors (93% [89-96]). We found that metastatic stage at diagnosis (HR = 3.1[1.3-7.6]; p = 0.01) and tumor size > 3 cm (HR = 2.7 [1.1-6.3]) were independent prognostic factors for OS in our population. CONCLUSIONS The survival rates of thyroid cancer in Martinique are comparable to those observed in France.
Collapse
Affiliation(s)
- Lyvio Lin
- CHU Martinique, UF1441 Registre Des Cancers de La Martinique, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
| | - Thierry Almont
- CHU Martinique, UF3596 Recherche en Cancérologie, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
| | - Murielle Beaubrun
- CHU Martinique, UF1441 Registre Des Cancers de La Martinique, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
| | - Jonathan Macni
- CHU Martinique, UF1441 Registre Des Cancers de La Martinique, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
| | - Aimée Pierre-Louis
- CHU Martinique, UF1441 Registre Des Cancers de La Martinique, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
| | - Audrey Zabulon
- Pôle Cardiovasculaire Thoracique Maladies Métaboliques Et Endocriniennes Néphrologie Hémodialyse, CHU Martinique, UF2151 Service d’endocrinologie, Fort de France, Martinique France
| | - Ciprian Draganescu
- CHU Martinique, UF1431, Médecine Nucléaire, Pôle Imagerie Médicale, Fort de France, Martinique France
| | - Lucien Lin
- Pôle Cardiovasculaire Thoracique Maladies Métaboliques Et Endocriniennes Néphrologie Hémodialyse, CHU Martinique, UF3540 Service d’endocrinologie, Fort de France, Martinique France
| | - Nadia Sabbah
- Service d’Endocrinologie, Centre Hospitalier de Cayenne, Guyane, France
| | - Moustapha Drame
- CHU de La Martinique, UF3163, Unité de Soutien Méthodologique À La Recherche (USMR), Délégation À La Recherche Clinique Et de L’Innovation (DRCI), Fort de France, Martinique France
| | - Jacqueline Veronique-Baudin
- CHU Martinique, UF3596 Recherche en Cancérologie, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
| | - Clarisse Joachim
- CHU Martinique, UF1441 Registre Des Cancers de La Martinique, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique France
- Hôpital Albert Clarac, Avenue PASTEUR, C.S 90632 97200 Fort de France, France
| |
Collapse
|
5
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ebring C, Marlin R, Macni J, Vallard A, Bergerac S, Beaubrun-Renard M, Joachim C, Jean-Laurent M. Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique. PLoS One 2023; 18:e0278757. [PMID: 36928660 PMCID: PMC10019642 DOI: 10.1371/journal.pone.0278757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Accepted: 11/22/2022] [Indexed: 03/18/2023] Open
Abstract
BACKGROUND AND STUDY AIMS In Martinique, about 33 new cases of endometrial cancer are diagnosed per year with a high mortality rate (world standardised rate of 4.9/100,000 versus 2.3/100,000 in mainland France). The present study aimed to determine the incidence and mortality of type I and type II endometrial cancers (ECs), their overall survival (OS) and disease-free survival (DFS) between 2012 and 2016. PATIENTS AND METHODS This retrospective observational cohort study used data from the Martinique Cancer Registry (MCR). 191 patients with corpus uterine cancer were extracted between 2012 and 2016. Patients with either endometrioid endometrial carcinoma (EEC), uterine papillary serous carcinomas (UPSC), uterine clear cell carcinomas (UCCC) or uterine carcinosarcomas (UCS) were included. All other uterine cancers were excluded. RESULTS Among the 163 included patients, 97 (60%) were type I and 66 (40%) were type II. The standardized incidence rate is 4.50/100,000 for type I vs. 2.66/100,000 for type II. Three years DFS for all types, type I and type II was 81.5% [74.2-86.9], 84.9% [75.4-91] and 76.7% [63.8-85.5] respectively. The five-years OS for all types, type I and type II was 47.0% [38.9-54.7] vs. 58.8% [47.3-68.5] vs. 22.8% [15.0-37.7] respectively. CONCLUSIONS In Martinique, we report a high proportion of type II ECs, which has a poor prognosis with few treatment options.
Collapse
Affiliation(s)
- Coralie Ebring
- Service de Gynécologie, Maison de la Femme de la Mère et de l’Enfant, CHU de Martinique, Fort-de-France, Martinique
| | - Régine Marlin
- Unité de Génétique Moléculaire des Cancers du CHU Martinique, Fort-de-France, Martinique
- * E-mail:
| | - Jonathan Macni
- UF 1441 Registre Général des Cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique
| | - Alexis Vallard
- Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique
| | - Sébastien Bergerac
- Service de Médecine Nucléaire, CHU de Martinique, Fort-de-France, Martinique
| | | | - Clarisse Joachim
- Unité de Génétique Moléculaire des Cancers du CHU Martinique, Fort-de-France, Martinique
| | - Mehdi Jean-Laurent
- Service de Gynécologie, Maison de la Femme de la Mère et de l’Enfant, CHU de Martinique, Fort-de-France, Martinique
| |
Collapse
|
7
|
Beaubrun-Renard MM, Veronique-Baudin J, Macni J, Ulric-Gervaise S, Almont T, Aline-Fardin A, Grossat N, Furtos C, Escarmant P, Vinh-Hung V, Bougas S, Cabie A, Joachim C. Overall survival of triple negative breast cancer in French Caribbean women. PLoS One 2022; 17:e0271966. [PMID: 36001624 PMCID: PMC9401158 DOI: 10.1371/journal.pone.0271966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 07/11/2022] [Indexed: 12/04/2022] Open
Abstract
To describe survival according to prognostic factors of women with breast cancer in French overseas territory (Martinique) during 2008–2017. We performed a Cox model for prognostic factors for OS in breast cancer patients. The cut-off date for the analysis was 13/10/2018. The main factors were demographic data, stage, hormone receptors (HR) status and HER2 status. Curves were compared with the log rank test to select candidate variables for the multivariate analysis. We included 1,708 patients; median age at diagnosis was 57 years. Triple negative breast cancer (TNBC) accounted for 20.9% (n = 332). Among the patients, 72.3% (n = 1015) had localised or local spread cancer. One-year OS was 95.2% and was 80.1% at 5 years. In TNBC, 1-year-survival was 90.4%, which fell to 70.1% at 5 years. Patients with metastatic disease at diagnosis had 1-year-survival of 74.5%, and 20.1% at 5 years. Multivariate analysis by Cox regression identified 4 factors significantly associated with an increased risk of death: metastatic disease at diagnosis (hazard ratio (HR) = 15, p<0.0001), TNBC (HR 2.84, p<0.0001), HR+/HER2- status (HR 2.05, p<0.0084) and age >75 years (HR 3.8, p<0.0001). This is the first study performed on breast cancer survival in Martinique. Our findings show that breast cancer has overall good prognosis in patients and also how prognosis factors are distributed in the population.
Collapse
Affiliation(s)
- Murielle Murielle Beaubrun-Renard
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
- PCCEI, Université de Montpellier, INSERM, EFS, Université Antilles, Montpellier, France
- * E-mail:
| | - Jacqueline Veronique-Baudin
- UF 3596 Recherche en cancérologie hématologie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Jonathan Macni
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Stephen Ulric-Gervaise
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Thierry Almont
- UF 3596 Recherche en cancérologie hématologie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Aude Aline-Fardin
- Laboratoire d’anatomopathologie, Pôle de Biologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Nathalie Grossat
- UF 1450 - Oncologie Médicale Hospitalisation de Semaine, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Cristina Furtos
- UF 1450 - Oncologie Médicale Hospitalisation de Semaine, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Patrick Escarmant
- Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Vincent Vinh-Hung
- UF 1401 Radiothérapie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - Stefanos Bougas
- UF 1401 Radiothérapie, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
| | - André Cabie
- PCCEI, Université de Montpellier, INSERM, EFS, Université Antilles, Montpellier, France
- Service des maladies infectieuses et tropicales, Martinique, CHU de Martinique, Fort-de-France, Martinique, France
- CIC-1424, INSERM, CHU de Martinique, Fort-de-France, Martinique, France
| | - Clarisse Joachim
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU de Martinique, Fort-de-France, Martinique, France
- PCCEI, Université de Montpellier, INSERM, EFS, Université Antilles, Montpellier, France
| |
Collapse
|
8
|
Imounga Desroziers L, Belliardo S, Deloumeaux J, Plenet J, Bhakkan-Mambir B, Péruvien J, Chatignoux E, Macni J, Boullard M, Beaubrun-Renard M, Véronique-Baudin J, Joachim C. Burden of gastric and digestive cancers in the French Caribbean: perspectives from population-based cancer registries of Martinique, Guadeloupe and French Guiana (2007-2014). BMJ Open 2022; 12:e047167. [PMID: 35110303 PMCID: PMC8811555 DOI: 10.1136/bmjopen-2020-047167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022] Open
Abstract
OBJECTIVES Data from population-based cancer registries contribute to improving our knowledge of digestive cancer trends worldwide. In this study, we present cancer incidence and mortality in Guadeloupe, French Guiana and Martinique for the periods 2008-2014, 2010-2014 and 2007-2014, respectively. DESIGN Data were extracted from population-based cancer registries. World-standardised incidence (WSI) and mortality (WSM) rates were calculated. Main digestive cancers were analysed, including oesophagus, stomach, colorectum, liver and pancreas cancers. SETTING This study was performed based on data from French Territories in the Caribbean. RESULTS We observed a lower-incidence compared with mainland France, except for stomach cancer for which the incidence is high, with significant standardised incidence ratios in men and women at 1.90 vs 2.29 for Guadeloupe and French Guiana and 1.58 vs 2.31 for Martinique. We found a lower-mortality, except for stomach cancer for which the mortality remains high, with significant mortality ratios in men and women at 2.10 vs 2.74 for Guadeloupe, 1.64 vs 1.79 for French Guiana and 2.05 vs 2.53 for Martinique. Overall, these three regions have similar WSI and WSM rates which remain lower than those in mainland France. We noticed an overall high incidence and high mortality in men compared with women as in France. CONCLUSIONS There is a high incidence of stomach cancer in French overseas territories. Publication of these data contributed to expanding knowledge on the epidemiology of world cancers with data from the Caribbean zone.
Collapse
Affiliation(s)
| | - Sophie Belliardo
- Registre Général des cancers de la Guyane, URPS Guyane, Cayenne, French Guiana
| | - Jacqueline Deloumeaux
- Registre Général des cancers de la Guadeloupe, Centre Hospitalier Universitaire de la Guadeloupe, Pointe-a-Pitre, Guadeloupe
| | - Juliette Plenet
- Registre Général des cancers de la Guyane, URPS Guyane, Cayenne, French Guiana
| | - Bernard Bhakkan-Mambir
- Registre Général des cancers de la Guadeloupe, Centre Hospitalier Universitaire de la Guadeloupe, Pointe-a-Pitre, Guadeloupe
| | - Jessica Péruvien
- Registre Général des cancers de la Guadeloupe, Centre Hospitalier Universitaire de la Guadeloupe, Pointe-a-Pitre, Guadeloupe
| | | | - Jonathan Macni
- Registre Général des cancers de la Martinique UF1441, Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique
| | - Manon Boullard
- Registre Général des cancers de la Martinique UF1441, Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique
| | - Murielle Beaubrun-Renard
- Registre Général des cancers de la Martinique UF1441, Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique
| | - Jacqueline Véronique-Baudin
- Unité Fonctionnelle Recherche en Cancérologie UF3596, Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique
| | - Clarisse Joachim
- Registre Général des cancers de la Martinique UF1441, Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique
| |
Collapse
|
9
|
Deloumeaux J, Bhakkan-Mambir B, Desroziers L, Plenet J, Peruvien J, Chatignoux É, Belliardo S, Macni J, Ulric-Gervaise S, Véronique-Baudin J, Joachim C. Urological Cancers in French Overseas Territories: A Population-Based Cancer Registry Pooled Analysis in Martinique, Guadeloupe and French Guiana (2007-2014). J Epidemiol Glob Health 2022; 12:232-238. [PMID: 35041179 PMCID: PMC9470795 DOI: 10.1007/s44197-022-00033-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 01/06/2022] [Indexed: 12/24/2022] Open
Abstract
Purpose Prostate cancer is the most common cancer in the Caribbean. We present world-standardized incidence (WSI) and mortality (WSM) rates for urological cancers for French overseas territories. Materials and Methods Standardized incidence ratio (SIR) and standardized mortality ratio (SMR) were calculated for 2008–2014, 2007–2014 and 2010–2014 in Guadeloupe, Martinique and French Guiana. Results For prostate cancer, in Guadeloupe and Martinique, the WSI rates are among the highest in the world (173.0 and 164.5 per 100,000 person-years) and 94.4 in French Guiana. Mortality remains more than twice that observed in mainland France, at 23.0 in Guadeloupe and Martinique, and 16.9 in French Guiana. For bladder cancer, WSI rates were 5.9, 4.9 and 4.1 in men, and 1.9, 1.4 and 1.3 in women, in French Guiana, Guadeloupe and Martinique. WSM rates from bladder varied from 1.5 in French Guiana to 1.8 in Guadeloupe and 2.0 in Martinique in men. In women, it ranges from 0.2 in French Guiana to 0.5 in Guadeloupe and 1.1 in Martinique. Regarding kidney, WSI rates in men are 4.3 in Martinique, 5.2 in Guadeloupe and 6.1 in French Guiana, and 2.3, 2.5 and 3.4, respectively, in women. Mortality rates in men were 1.7 in Guadeloupe, 1.4 in Martinique, and 1.5 in French Guiana, while in women, rates were 0.8 in Guadeloupe and Martinique and 0.6 in French Guiana. All these rates are lower than in mainland France. Conclusions Identifying the profile of patients with urological cancers is key to understanding the needs of patients in these regions.
Collapse
Affiliation(s)
- Jacqueline Deloumeaux
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I., Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | - Bernard Bhakkan-Mambir
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I., Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | | | | | - Jessica Peruvien
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I., Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | - Édouard Chatignoux
- French National Public Health Agency, 12 rue du Val d’Osne, 94410 Saint Maurice, France
| | | | - Jonathan Macni
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
| | - Stephen Ulric-Gervaise
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
| | - Jacqueline Véronique-Baudin
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
| | - Clarisse Joachim
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
- Hôpital Albert Clarac, Avenue Pasteur, CS 90632, 97200 Fort de France, Martinique
| |
Collapse
|
10
|
Najioullah F, Dorival MJ, Joachim C, Dispagne C, Macni J, Abel S, Sulpicy C, Charpentier-Baltide H, Sainte-Rose D, Salomon-Frechou B, Dieye M, Véronique-Baudin J, Pré M, Marquet M, Wan-Ajouhu G, Janky E, Riethmuller D, Cesaire R. Genotype distribution of cervical HPV among Caribbean women in a population-based study in Martinique: The DEPIPAPUFR study. PLoS One 2021; 16:e0257915. [PMID: 34618835 PMCID: PMC8496807 DOI: 10.1371/journal.pone.0257915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 09/13/2021] [Indexed: 12/09/2022] Open
Abstract
The Caribbean ranks seventh among the world regions most affected by cervical cancer. HPV-prevalence and genotype distributions also differ from regions. Knowledge of HPV genotype profiles is important for patients care and HPV vaccination implementation. The objective of this study was to describe HPV genotype distribution and risk factors in a population-based cohort of women in Martinique. In this study, 1312 women were included and underwent cervical cancer screening with successful sample collection between 2009 and 2014. Sociodemographic and clinical variables were recorded. Cytological examination of cervical vaginal smear was performed and classified(Bethesda). Detection of HPV DNA was performed with the PapilloCheck© Kit from Greiner Bio-one. Genotypes were analyzed for18 high-risk HPV (hrHPV) and 6low-risk HPV(lrHPV) types. A total of 1075 women were included with a mean age of 49.1±10.5 years. HPV prevalence was 27.6% (297/1075) with 19.4% (209/1075) women with only hrHPV, 5.3% (57/1075) with only lrHPV. Multiple infections (hrHPV/lrHPV) were detected in 31/240 cases of hrHPV (12.9%). A total of 353 hrHPV genotypes were analyzed; the most common HPV types were HPV51 (11.0%), HPV68 (10.8%), HPV53 (9.1%) and HPV 52 (7.1%). HPV16 and HPV18 represented respectively 4.8% and 4.0% of hrHPV genotypes. Abnormal cytology was observed in 34 cases (3.2%), with 14 ASCUS (1.3%), 10 LSIL (0.9%), 5 HSIL (0.5%), 3 ASC-H (0.3%) and 2 AGC (0.2%). Fifteen (44.1%) were hrHPV and 4 (14.7%) lrHPV; 7 cases of hrPHV were in the age-group 25-34 years. Among 1041cases of normal cytology, 225 had positive hrHPV detection (21.6%). This is the first population-based study of HPV profiles in our country, and we found a high prevalence of hrHPV. The most common genotypes were HPV51, 68, 53. These results could serve for cancer vaccination strategies and HPV surveillance in Martinique.
Collapse
Affiliation(s)
- Fatiha Najioullah
- CHU de Martinique, Pôle de Biologie - Pathologie, Laboratoire de Virologie, Martinique, France
| | | | - Clarisse Joachim
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF1441 Registre Général des cancers de la Martinique, Martinique, France
- * E-mail:
| | | | - Jonathan Macni
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF1441 Registre Général des cancers de la Martinique, Martinique, France
| | - Sylvie Abel
- Service de Maladies Infectieuses et Tropicales, CHU de Martinique, Martinique, France
| | - Caroline Sulpicy
- Laboratoire de Pathologie SERAL, Fort-de-France, Martinique, France
| | | | | | | | | | - Jacqueline Véronique-Baudin
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF1441 Registre Général des cancers de la Martinique, Martinique, France
| | | | | | | | - Eustase Janky
- CHU de Guadeloupe-Laboratory CELTEC Cancer and Environment EA4546, Université des Antilles, Guadeloupe, France
| | - Didier Riethmuller
- Service de Gynécologie Obstétrique, CHRU de Besançon - Hôpital Jean Minjoz, Besançon, France
| | - Raymond Cesaire
- CHU de Martinique, Pôle de Biologie - Pathologie, Laboratoire de Virologie, Martinique, France
| | | |
Collapse
|
11
|
Joachim C, Véronique-Baudin J, Desroziers L, Chatignoux É, Belliardo S, Plenet J, Macni J, Ulric-Gervaise S, Peruvien J, Bhakkan-Mambir B, Deloumeaux J. Gynaecological cancer in Caribbean women: data from the French population-based cancer registries of Martinique, Guadeloupe and French Guiana (2007-2014). BMC Cancer 2020; 20:643. [PMID: 32650744 PMCID: PMC7350571 DOI: 10.1186/s12885-020-07128-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Accepted: 07/02/2020] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND For the first time, we present regional-level cancer incidence and world-standardized mortality rates for cancers for Martinique, Guadeloupe and French Guiana. METHODS For Martinique, Guadeloupe and French Guiana, incidence data come from population-based cancer registries, and cover the periods 2007-2014, 2008-2014 and 2010-2014 respectively. Standardized incidence and mortality rates were calculated using the world population. RESULTS In the 3 regions, all cancers combined represent 3567 new cases per year, of which 39.8% occur in women, and 1517 deaths per year (43.4% in women). Guadeloupe and Martinique present similar world-standardized incidence rates. Among gynaecological cancers, breast cancer, the second most common cancer type in the 3 regions, has an incidence rate 35 to 46% lower than in mainland France. On the other hand, cervical cancer has a higher incidence rate, particularly in French Guiana. For both endometrial cancer and ovarian cancer, no significant differences in incidence rates are found compared to mainland France. Regarding mortality, world-standardized mortality rates are similar between Guadeloupe and Martinique, and higher than in French Guiana. This situation compares favourably with mainland France (all cancers). Among gynaecological cancers, the mortality rate is lower for breast cancer in all regions compared to mainland France, and also lower for ovarian cancer in Martinique and Guadeloupe, but higher (albeit non-significantly) in French Guiana. CONCLUSION The ethno-geographic and socio-demographic characteristics in this population of mainly Afro-Caribbean origin could partially explain these disparities. Major disparities exist for certain cancer sites: excess incidence and excess mortality for cervical cancer; lower, but increasing incidence of breast cancer.
Collapse
Affiliation(s)
- Clarisse Joachim
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, UF 1441 Registre Général des cancers de la Martinique, F-97200 Martinique, France
- French Network of Cancer Registries, F-31000 Toulouse, France
| | - Jacqueline Véronique-Baudin
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, UF 1441 Registre Général des cancers de la Martinique, F-97200 Martinique, France
| | - Laure Desroziers
- French Network of Cancer Registries, F-31000 Toulouse, France
- Registre général des cancers de la Guyane, Guyane, France
| | - Édouard Chatignoux
- French National Public Health Agency, 12 rue du Val d’Osne, 94410 Saint Maurice, France
| | - Sophie Belliardo
- French Network of Cancer Registries, F-31000 Toulouse, France
- Registre général des cancers de la Guyane, Guyane, France
| | - Juliette Plenet
- French Network of Cancer Registries, F-31000 Toulouse, France
- Registre général des cancers de la Guyane, Guyane, France
| | - Jonathan Macni
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, UF 1441 Registre Général des cancers de la Martinique, F-97200 Martinique, France
- French Network of Cancer Registries, F-31000 Toulouse, France
| | - Stephen Ulric-Gervaise
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, UF 1441 Registre Général des cancers de la Martinique, F-97200 Martinique, France
- French Network of Cancer Registries, F-31000 Toulouse, France
| | - Jessica Peruvien
- French Network of Cancer Registries, F-31000 Toulouse, France
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I. Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | - Bernard Bhakkan-Mambir
- French Network of Cancer Registries, F-31000 Toulouse, France
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I. Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | - Jacqueline Deloumeaux
- French Network of Cancer Registries, F-31000 Toulouse, France
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I. Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| |
Collapse
|
12
|
Joachim C, Veronique-Baudin J, Vinh-Hung V, Contaret C, Macni J, Godaert L, Escarmant P, Farid K, Novella JL, Drame M, Tortolero-Luna G, Babie PT, Zavala DE, Alvarez YG. Building capacity for cancer surveillance and public health research: The Cancer Task Force Project for Cooperation in the Caribbean and Aging Research. J Glob Health 2020; 9:020304. [PMID: 31360443 PMCID: PMC6642813 DOI: 10.7189/jogh.09.020304] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Affiliation(s)
- Clarisse Joachim
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU Martinique, Fort-de-France, Martinique
| | - Jacqueline Veronique-Baudin
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU Martinique, Fort-de-France, Martinique
| | - Vincent Vinh-Hung
- Pôle de Cancérologie Hématologie Urologie, CHU Martinique, Fort-de-France, Martinique
| | - Cédric Contaret
- UF 3163, Délégation de la Recherche et de l'innovation, CHU de Martinique, Martinique
| | - Jonathan Macni
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, CHU Martinique, Fort-de-France, Martinique
| | - Lidvine Godaert
- Pôle de Gériatrie, CHU de Martinique, Fort-de-France, Martinique
| | - Patrick Escarmant
- Pôle de Cancérologie Hématologie Urologie, CHU Martinique, Fort-de-France, Martinique
| | - Karim Farid
- Pole d'imagerie Médicale Service de Médecine nucléaire, CHU Martinique, Martinique
| | - Jean-Luc Novella
- Faculté de Médecine, EA 3797, Université de Reims Champagne- Ardenne, Reims, France.,Département de Médecine Interne et Gériatrie, CHU de Reims, Reims, France
| | - Moustapha Drame
- Faculté de Médecine, EA 3797, Université de Reims Champagne- Ardenne, Reims, France.,Unité d'aide Méthodologique, Pôle Recherche et Santé publique, CHU de Reims, Reims, France
| | - Guillermo Tortolero-Luna
- University of Puerto Rico, San Juan, Puerto Rico.,Puerto Rico Central Cancer Registry, Comprehensive Cancer Center, San Juan, Puerto Rico
| | | | - Diego E Zavala
- University of Puerto Rico, San Juan, Puerto Rico.,Puerto Rico Central Cancer Registry, Comprehensive Cancer Center, San Juan, Puerto Rico
| | - Yaima Galan Alvarez
- Registro Nacional de Cáncer de Cuba, Sección Independiente para el Control del Cáncer, Instituto Nacional de Oncología y Radiobiología, Habana, Cuba
| |
Collapse
|
13
|
Joachim C, Macni J, Drame M, Pomier A, Escarmant P, Veronique-Baudin J, Vinh-Hung V. Overall survival of colorectal cancer by stage at diagnosis: Data from the Martinique Cancer Registry. Medicine (Baltimore) 2019; 98:e16941. [PMID: 31464932 PMCID: PMC6736397 DOI: 10.1097/md.0000000000016941] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Population-based cancer registries (PBCR) participate in epidemiological surveillance and in the evaluation of cancer types by enabling analysis of incidence and survival data over time. The aim of this study was to examine overall survival (OS) in patients with colorectal cancer (CRC) by analyzing data from the Martinique population-based cancer registry between 1993 and 2012. All colorectal cancer cases diagnosed in Martinique between 1993 and 2012 were included. Characteristics of CRC patients were analyzed according to age subgroups, namely: <50 years, 50 to 74 years and over 75 years.We recorded the following socio-demographic and clinical variables: year of diagnosis, age at diagnosis, sex, histology, zone of residence, and subsite of the cancer. Incidence of malignant neoplasms of the colon and rectum (ICD-10 C18-21) was extracted from the Martinique Cancer Registry database. Stage at diagnosis (localized: stage I-II, regional: stage III and metastatic stage: stage IV) were also analyzed for the 2008 to 2012 period.A total of 2230 cases of incident invasive CRC were included during the study period (1993-2012): 1171 were women (52.5%); 1588 patients (71.2%) had colon cancer. Stage at diagnosis was evaluated in 779 patients (89.6%): 486/779 (62.4%) had stage III-IV at diagnosis, including 285 (36.6%) patients with metastases at diagnosis (stage IV). One-year, 5-year and 10-year OS for the study period 1993 to 2012 was 74.6%, 43.8% and 33.0% respectively. There was a statistical difference in overall survival according to gender (P = .0153), age at diagnosis (P < .001) and stage (P < .001).Median OS was 2.0 years (95% CI [1.4-2.1]) in the stage III-IV group during the period 2008 to 2012, whereas it was unreached in the stage I-II group. Multivariable analysis confirmed that stage III-IV at diagnosis (hazard ratio (HR) = 3.70 [2.89-4.99]; P < .0001) and colon cancer (HR = 1.30 [1.01-1.69]; P = .04) were main prognostic factors for OS. Women had a HR of 0.78 [0.62-0.96], P = .02. CRC patients in the 50 to 74 years age group had a HR of 0.63 [0.50-0.80], P = .0001.This study underlines the importance of structuring management of CRC cancer patients.
Collapse
Affiliation(s)
- Clarisse Joachim
- CHU Martinique, UF1441 Registre des Cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, Martinique, France
| | - Jonathan Macni
- CHU Martinique, UF1441 Registre des Cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, Martinique, France
| | - Moustapha Drame
- CHU Martinique, Unité de Soutien Méthodologique à la Recherche, Martinique, France
| | - Audrey Pomier
- Association Martiniquaise pour la Recherche Epidémiologique en Cancérologie, Registre Général des Cancers de la Martinique, Martinique, France
| | - Patrick Escarmant
- CHU Martinique, Pôle de Cancérologie Hématologie Urologie, CHU Martinique, Martinique, France
| | - Jacqueline Veronique-Baudin
- CHU Martinique, UF1441 Registre des Cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie, Martinique, France
| | - Vincent Vinh-Hung
- CHU Martinique, Pôle de Cancérologie Hématologie Urologie, Martinique, France
| |
Collapse
|
14
|
Joachim C, Veronique-Baudin J, Ulric-Gervaise S, Pomier A, Pierre-Louis A, Vestris M, Novella JL, Drame M, Macni J, Escarmant P. Cancer burden in the Caribbean: an overview of the Martinique Cancer Registry profile. BMC Cancer 2019; 19:239. [PMID: 30876409 PMCID: PMC6420743 DOI: 10.1186/s12885-019-5434-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Accepted: 03/04/2019] [Indexed: 01/01/2023] Open
Abstract
Background Cancer indicators are essential information for cancer surveillance and cancer research strategy development. The Martinique Cancer Registry (MCR) is a population-based cancer Registry (PBCR) that has been recording cancer data since its creation in 1981. This article provides cancer incidence and mortality data for all cancers and for major tumor sites. Methods The registry collects all new cancer cases, details of the individual affected, tumor site and follow-up. World-standardized incidence and mortality rates were calculated, by tumor site and sex for solid tumors from the MCR database for the study period 2001–2015. Results Over the period 2001–2015, a total of 22,801 new cases were diagnosed; 13,863 in men (60.8%) and 8938 in women (39.2%). In 2011–2015, 1631 new cases were diagnosed per year. Age-standardized (to the world population) incidence rates for all cancers, were 289.8 per 100,000 men and 171.0 per 100,000 women. Breast, colon-rectum and stomach were the most common cancer sites in women. Prostate, colon-rectum and stomach were the main sites in men. Martinique has higher incidence rates of prostate and stomach cancer than mainland France. Conclusions Prostate and stomach cancers have high incidence and rank first among the four major tumor sites. Providing data for the French zone of the Caribbean is essential to contributing to the development of high-priority public health measures for the Caribbean zone.
Collapse
Affiliation(s)
- Clarisse Joachim
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, Fort-de-France, Martinique.
| | - Jacqueline Veronique-Baudin
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, Fort-de-France, Martinique
| | - Stephen Ulric-Gervaise
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, Fort-de-France, Martinique
| | - Audrey Pomier
- Association Martiniquaise pour la Recherche en Cancérologie en Martinique, Registre Général des cancers de la Martinique, Fort-de-France, Martinique
| | - Aimée Pierre-Louis
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, Fort-de-France, Martinique
| | - Mylène Vestris
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, Fort-de-France, Martinique
| | | | - Moustapha Drame
- CHU de Martinique, UF 3163, Unité de soutien méthodologique à la Recherche, Délégation de la Recherche et de l'innovation, Fort-de-France, Martinique
| | - Jonathan Macni
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, Fort-de-France, Martinique
| | - Patrick Escarmant
- CHU Martinique, Pôle de Cancérologie Hématologie, Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| |
Collapse
|
15
|
Joachim C, Ulric-Gervaise S, Dramé M, Macni J, Escarmant P, Véronique-Baudin J, Vinh-Hung V. Long-term survival of patients with prostate cancer in Martinique: Results of a population-based study. Cancer Epidemiol 2019; 59:193-198. [PMID: 30825842 DOI: 10.1016/j.canep.2019.02.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 02/04/2019] [Accepted: 02/08/2019] [Indexed: 12/27/2022]
Abstract
BACKGROUND Martinique has one of the highest incidences of prostate cancer (PCa) worldwide. We analysed overall survival (OS) among patients with PCa in Martinique, using data from a population-based cancer registry between 2005 and 2014. METHODS The log-rank test was used to assess the statistical differences between survival curves according to age at diagnosis, risk of disease progression including Gleason score, stage at diagnosis and Prostate Specific Antigen (PSA). A multivariable Cox model was constructed to identify independent prognostic factors for OS. RESULTS A total of 5045 patients were included with a mean age at diagnosis of 68.1±9.0 years [36.0 - 98.0 years]. Clinical stage was analysed in 4999 (99.1% of overall), 19.5% were at low risk, 34.7% intermediate and 36.9% at high risk. In our study, 8.9% of patients with available stage at diagnosis, were regional/metastatic cancers. Median PSA level at diagnosis was 10.4 ng/mL. High-risk PCa was more frequent in patients aged 65-74 and ≥75 years as compared to those aged <65 years (36.6% and 48.8% versus 28.7% respectively; p<0.0001). One-year OS was 96.3%, 5-year OS was 83.4 and 10-year OS was 65.0%. Median survival was not reached in the whole cohort. High-risk PCa (HR=2.32; p<0.0001), regional/metastatic stage (HR= 9.51; p<0.0001) and older age (65-74 and ≥75 years - respectively HR=1.70; and HR=3.38), were independent prognostic factors for OS (p<0.0001). CONCLUSION This study provides long term data that may be useful in making cancer management decisions for patients with PCa in Martinique.
Collapse
Affiliation(s)
- Clarisse Joachim
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200, Fort-de-France, Martinique.
| | - Stephen Ulric-Gervaise
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200, Fort-de-France, Martinique
| | - Moustapha Dramé
- UF 3163, Unité de soutien méthodologique à la Recherche, Délégation de la Recherche et de l'innovation, CHU Martinique, 97200, Fort-de-France, Martinique
| | - Jonathan Macni
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200, Fort-de-France, Martinique
| | - Patrick Escarmant
- Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200, Fort-de-France, Martinique
| | - Jacqueline Véronique-Baudin
- UF 1441 Registre Général des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200, Fort-de-France, Martinique
| | - Vincent Vinh-Hung
- Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200, Fort-de-France, Martinique
| |
Collapse
|
16
|
Joachim C, Veronique-Baudin J, Ulric-Gervaise S, Macni J, Almont T, Pierre-Louis O, Godaert L, Drame M, Novella JL, Farid K, Vinh-Hung V, Escarmant P. Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean. BMC Cancer 2018; 18:1130. [PMID: 30445934 PMCID: PMC6240273 DOI: 10.1186/s12885-018-5047-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 11/06/2018] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The French West-Indies rank first for both prostate cancer incidence and mortality rates. Analyzing diagnostic and therapeutic procedures among patients with prostate cancer, using data from a population-based cancer registry, is essential for cancer surveillance and research strategies. METHODS This retrospective observational cohort study was based on data from the Martinique Cancer Registry. Records of 452 patients diagnosed with prostate cancer in 2013 were retrieved from the registry. Data extracted were: socio-demographic and clinical characteristics, circumstances of diagnosis, PSA level at diagnosis, Gleason score and risk of disease progression. Stage at diagnosis and patterns of care among prostate cancer patients were analyzed. RESULTS Mean age at diagnosis was 67 ± 8 years; 103 (28.5%) were symptomatic at diagnosis. Digital rectal exam was performed in 406 (93.8%). Clinical stage was available in 385 (85.2%); tumours were localized in 322/385 (83.6%). Overall, 17.9% were at low risk, 36.4% at intermediate and 31.9% at high risk; 13.8% were regional/metastatic cancers. Median PSA level at diagnosis was 8.16 ng/mL (range 1.4-5000 ng/mL). A total of 373 patients (82.5%) received at least one treatment, while 79 (17.5%) had active surveillance or watchful waiting. Among patients treated with more than one therapeutic strategy, the most frequent combination was external radiotherapy with androgen deprivation (n = 102, 22.6%). CONCLUSIONS This study provides detailed data regarding the quality of diagnosis and management of patients with prostate cancer in Martinique. Providing data on prostate cancer is essential for the development of high-priority public health measures for the Caribbean.
Collapse
Affiliation(s)
- Clarisse Joachim
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France.
| | - Jacqueline Veronique-Baudin
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France
| | - Stephen Ulric-Gervaise
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France
| | - Jonathan Macni
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France
| | - Thierry Almont
- CHU Toulouse Paule de Viguier, Groupe de recherche en fertilité humaine EA 3694, Toulouse, France.,Groupe d'Étude, de Formation et de Recherche en Andrologie, Urologie et Sexologie Médecine de la Reproduction, Toulouse, France
| | - Olivier Pierre-Louis
- CHU Martinique, Pôle de Cancérologie, Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France
| | - Lidvine Godaert
- CHU de Martinique, Pôle de Gériatrie, 97200 Fort-de-France, Martinique, France
| | - Moustapha Drame
- CHU de Reims, Pôle Recherche et Santé publique, 51100 Reims, France
| | | | - Karim Farid
- CHU Martinique, Pole d'imagerie Médicale Service de Médecine nucléaire, 97200 Fort-de-France, Martinique, France
| | - Vincent Vinh-Hung
- CHU MARTINIQUE, Pôle de Cancérologie Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France
| | - Patrick Escarmant
- CHU MARTINIQUE, Pôle de Cancérologie Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France
| |
Collapse
|
17
|
Melan K, Janky E, Macni J, Ulric-Gervaise S, Dorival MJ, Veronique-Baudin J, Joachim C. Epidemiology and survival of cervical cancer in the French West-Indies: data from the Martinique Cancer Registry (2002-2011). Glob Health Action 2018. [PMID: 28649938 PMCID: PMC5496169 DOI: 10.1080/16549716.2017.1337341] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: The Caribbean ranks seventh among world regions most affected by cervical cancer. Social health inequalities, such as differences in access to screening services, engender disparities in incidence and mortality between low- and middle-income countries and industrialized countries. The French National Cancer Plan 2014–2019 focuses on reducing inequalities in cervical cancer. Objective: The aim of this study was to describe the geographical distribution and overall survival of cervical cancer, based on data from a population-based cancer registry in Martinique (French West-Indies). Methods: We included all cases of cervical cancer diagnosed between 2002 and 2011. The geographical distribution was described by zone of residence and by aggregated units for statistical information (IRIS). Based on the results of the model, standardized incidence rates (SIRs) were calculated using a Gamma Poisson model. Survival rates were calculated using the Kaplan–Meier method. Cox proportional hazards models were used to investigate the risk factors for cervical cancer mortality. Results: A total of 1253 cases were analyzed (947 in situ tumors and 306 invasive cancers). 1230 cases with geolocalization were used to map the distribution of the incidence of in situ and invasive cervical cancers. Five IRIS were significantly over-incident. The 5-year overall survival rate was 55%, with a median survival of 6.5 years [95% CI: 4.9–10.1]. Multivariate analysis confirmed age at diagnosis (HR = 2.15 [1.50–3.09]; p < 0.0001), FIGO stage (HR = 3.53 [2.50–4.99]; p < 0.0001) and zone of residence (HR = 1.51 [1.06–2.13]; p = 0.02) as risk factors. Conclusions: Prognostic factors suggest that cervical cancer needs to be diagnosed at an early stage. Our results could allow cervical cancer screening programs to clearly identify geographical areas that would benefit from targeted interventions with a view to reducing incidence and mortality of cervical cancer in the Caribbean.
Collapse
Affiliation(s)
- K Melan
- a Martinique Cancer Registry , AMREC , Fort-de-France , Martinique
| | - E Janky
- b Gynecology Obstetrics Department , University Hospital of Pointe-à-Pitre , Pointe-à-Pitre , Guadeloupe
| | - J Macni
- c Oncology Haematology Urology Pathology Department , University Hospital of Martinique , Fort-de-France , Martinique
| | - S Ulric-Gervaise
- c Oncology Haematology Urology Pathology Department , University Hospital of Martinique , Fort-de-France , Martinique
| | - M-J Dorival
- d Laboratoire de Pathologie SERAL , Fort-de-France , Martinique
| | - J Veronique-Baudin
- c Oncology Haematology Urology Pathology Department , University Hospital of Martinique , Fort-de-France , Martinique
| | - C Joachim
- c Oncology Haematology Urology Pathology Department , University Hospital of Martinique , Fort-de-France , Martinique
| |
Collapse
|
18
|
Joachim C, Veronique-Baudin J, Almont T, Ulric-Gervaise S, Macni J, Pierre-Louis O, Godaert L, Drame M, Novella JL, Farid K, Vinh-Hung V, Escarmant P. Cohort profile: the Martinique Cancer Registry and the quality of life prostate cancer cohort (QoL Prostate-MQ): challenges and prospects for reducing disparities in the Caribbean. BMJ Open 2018; 8:e021540. [PMID: 30049695 PMCID: PMC6067331 DOI: 10.1136/bmjopen-2018-021540] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
PURPOSE Recording cancer data in cancer registries is essential for producing reliable population-based data for service planning, monitoring and evaluation. Prostate cancer (PCa) remains the most frequent type of cancer in terms of incidence and mortality in men in the Caribbean. The quality of life PCa cohort will assess quality of life and patient outcomes in Martinique using a digital platform for patient-reported outcome measures. PARTICIPANTS The Martinique Cancer Registry database is the largest clinical database among the French population-based cancer registries in the Caribbean, including more than 38 000 cancer cases, with 1650 new cancer cases per year, including 550 new PCa cases per year (2010-2014 latest period). In 2018, follow-up will include vital status, assessment of quality of life with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 and the Prostate cancer module QLQ-PR25. Urinary incontinence and erectile dysfunction recorded prior to treatment will be analysed 1 and 5 years after treatment. FINDINGS TO DATE The registry includes data on circumstances of diagnosis, clinical stage at diagnosis. For PCa, the registry includes blood prostate-specific antigen level at the time of diagnosis, Gleason score and primary treatment. FUTURE PLANS Further studies will provide detailed data regarding the quality of diagnosis and management of patients with PCa in Martinique; analysing quality of care will be the next challenge.Quality of life and patient outcomes will be evaluated using a digital platform for patient-reported outcome measurement and electronic records.
Collapse
Affiliation(s)
- Clarisse Joachim
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| | - Jacqueline Veronique-Baudin
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| | - Thierry Almont
- Groupe d’Étude, de Formation et de Recherche en Andrologie, Urologie et Sexologie Médecine de la Reproduction, Toulouse, France
- Groupe de recherche en fertilité humaine, CHU Toulouse Paule de Viguier, Toulouse, France
| | - Stephen Ulric-Gervaise
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| | - Jonathan Macni
- UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| | - Olivier Pierre-Louis
- Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| | - Lidvine Godaert
- Pôle de Gériatrie, CHU de Martinique, Fort-de-France, Martinique
| | - Moustapha Drame
- Unité d’aide Méthodologique, Pôle Recherche et Santé publique, CHU de Reims, Reims, France
- EA 3797, Université de Reims Champagne-Ardenne, Faculté de Médecine, Reims, France
| | - Jean-Luc Novella
- EA 3797, Université de Reims Champagne-Ardenne, Faculté de Médecine, Reims, France
- Département de Médecine Interne et Gériatrie, CHU de Reims, Reims, France
| | - Karim Farid
- Service de Médecine nucléaire, Pole d’imagerie Médicale, CHU Martinique, Fort-de-France, Martinique
| | - Vincent Vinh-Hung
- Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| | - Patrick Escarmant
- Pôle de Cancérologie Hématologie Urologie Pathologie, CHU Martinique, Fort-de-France, Martinique
| |
Collapse
|
19
|
Joachim C, Godaert L, Dramé M, Véronique-Baudin J, Macni J, Smith-Ravin J, Novella JL, Mahmoudi R. Overall survival in elderly patients with colorectal cancer: A population-based study in the Caribbean. Cancer Epidemiol 2017; 48:85-91. [PMID: 28426981 DOI: 10.1016/j.canep.2017.03.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 03/15/2017] [Accepted: 03/18/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND Population-based Cancer registries (PBCR) play an important role in cancer surveillance and research. The aim of this study was to examine overall survival in elderly patients with colorectal cancer (CRC) by analysing data from the Martinique PBCR between 1993 and 2012. METHODS The log-rank test was used to assess the statistical differences of the survival curves by each categorical variable: age at diagnosis, sex, histology, zone of residence, subsite, stage at diagnosis, and chemotherapy. A multivariable Cox model was performed to identify independent prognostic factors for overall survival in elderly patients with colorectal cancer. RESULTS Among 2230 patients included in the study, 60.8% were aged≥65years; mean age at diagnosis of these patients was 75.7±7.2years. For the period 2008-2012, 532 elderly patients were analysed; mean age of those receiving chemotherapy was 73.0±0.4 versus 77.9±0.4years for those not receiving chemotherapy (p<0.0001). Stage at diagnosis was evaluated in 87.8% (467/532) of patients; 63.0% (294/467) had stage III-IV and 49.3% of these patients (145/294) received chemotherapy. Chemotherapy was less frequently prescribed in patients aged 75-84 and ≥85 years as compared to those aged 65-74 years (41.1% and 15.0% versus 64.6% respectively; p<0.0001). Stage III-IV at diagnosis (HR=5.25; 3.70-7.45; p<0.0001), and not receiving chemotherapy (HR=3.05; 2.23-4.16; p<0.0001), were independent prognostic factors for overall survival. CONCLUSION Our study highlights the role of PBCR in evaluating cancer survival and patterns of care in elderly people of the French West- Indies. Chemotherapy was less frequently prescribed among the elderly.
Collapse
Affiliation(s)
- Clarisse Joachim
- Registre Général des cancers de la Martinique, UF 1441 Registre des cancers, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200 Fort-de-France, Martinique, France.
| | - Lidvine Godaert
- Pôle de Gériatrie, CHU de Martinique, 97200 Fort-de-France, Martinique, France
| | - Moustapha Dramé
- Faculté de Médecine, EA 3797, Université de Reims Champagne-Ardenne, 51095 Reims, France; Unité d'aide Méthodologique, Pôle Recherche et Santé publique, CHU de Reims, 51000 Reims, France
| | - Jacqueline Véronique-Baudin
- Registre Général des cancers de la Martinique, UF 1441 Registre des cancers, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200 Fort-de-France, Martinique, France
| | - Jonathan Macni
- Registre Général des cancers de la Martinique, UF 1441 Registre des cancers, Pôle de Cancérologie Hématologie Urologie Pathologie, CHU de Martinique, 97200 Fort-de-France, Martinique, France
| | - Juliette Smith-Ravin
- Université des Antilles, EA929 groupe BIOSPHERES, Campus de Schœlcher, 97200 Fort-de-France, Martinique, France
| | - Jean-Luc Novella
- Faculté de Médecine, EA 3797, Université de Reims Champagne-Ardenne, 51095 Reims, France; Département de Médecine Interne et Gériatrie, CHU de Reims, 51000 Reims, France
| | - Rachid Mahmoudi
- Faculté de Médecine, EA 3797, Université de Reims Champagne-Ardenne, 51095 Reims, France; Département de Médecine Interne et Gériatrie, CHU de Reims, 51000 Reims, France
| |
Collapse
|
20
|
Dieye M, Banydeen R, Macni J, Michel S, Veronique-Baudin J, Sasco A, Escarmant P, Joachim C. Geographic variations and temporal trends in prostate cancer in Martinique over a 25-year period. BMC Res Notes 2014; 7:262. [PMID: 24758582 PMCID: PMC4013304 DOI: 10.1186/1756-0500-7-262] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Accepted: 04/03/2014] [Indexed: 11/22/2022] Open
Abstract
Background In Martinique, prostate cancer incidence rates have been increasing since the 1980s and are actually among the highest worldwide. Exposure to lifestyle (changes in dietary habits), environmental factors (exposure to organochlorine pesticides) and modifications in diagnostic and screening procedures, are favored etiological hypotheses. The aim of the present study is to describe and interpret prostate cancer incidence trends over the past 25 years (1981–2005) in Martinique. Methods Data on incident prostate cancer cases from 1981 to 2005 were obtained from the population-based Martinique Cancer Registry. World age-standardised incidence rates were calculated and an age-period-cohort model was used to determine average annual variations for prostate cancer during the study period. Age and period effects were assessed, employing the method proposed by Clayton and Schifflers. Relative changes in prostate cancer incidence, at five-year intervals between 1981 and 2005, were also studied with an organochlorine pesticide exposure index, built as a proxy of the relative intensity of chlordecone use on the island between 1973 and 1993. Results Prostate cancer incidence was found to increase by 5.07% annually between 1981 and 2005. Compared to 1981–1985, prostate cancer relative risk, in men aged 50–74 years and 75 years and above was respectively 5.98% and 3.07% from 2001 to 2005. An inverse association between population pesticide exposure levels and prostate cancer risk was also highlighted, with highest prostate cancer incidences observed in urban zones showing the lowest soil contamination levels by the chlordecone pesticide (zone 1). Conclusion No conclusive association was found between the intensity of pesticide use and the subsequent rise in prostate cancer incidence. However, it remains necessary to develop and reinforce continuous monitoring of prostate cancer incidence and mortality trends on the island. Further studies are also needed in order to consider other risk factors such as modifications in diagnostic and screening procedures over the last 25 years.
Collapse
Affiliation(s)
| | | | | | | | - Jacqueline Veronique-Baudin
- Pôle de Cancérologie Hématologie Urologie, Registre des Cancers de la Martinique - UF 1441 Recherche & Registre, Centre Hospitalier Universitaire de la Martinique, 127 Route de Redoute, Fort-de-France 97200, Martinique.
| | | | | | | |
Collapse
|